Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) Short Interest Up 254.8% in March

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) was the target of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 51,800 shares, a growth of 254.8% from the February 28th total of 14,600 shares. Based on an average daily trading volume, of 85,100 shares, the short-interest ratio is currently 0.6 days. Currently, 0.0% of the shares of the company are sold short.

Fresenius SE & Co. KGaA Trading Up 0.5 %

OTCMKTS:FSNUY opened at $10.92 on Friday. The firm has a market capitalization of $24.40 billion, a P/E ratio of 52.00 and a beta of 1.02. The business has a 50 day simple moving average of $10.16 and a 200 day simple moving average of $9.45. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.36 and a quick ratio of 1.05. Fresenius SE & Co. KGaA has a 12-month low of $6.57 and a 12-month high of $11.23.

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) last released its quarterly earnings results on Wednesday, February 26th. The company reported $0.18 EPS for the quarter. The firm had revenue of $6.01 billion for the quarter. Equities research analysts predict that Fresenius SE & Co. KGaA will post 0.79 EPS for the current year.

Analysts Set New Price Targets

Separately, Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Fresenius SE & Co. KGaA in a report on Monday, February 3rd.

About Fresenius SE & Co. KGaA

Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.